Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost
Executive Summary
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
You may also be interested in...
Can Moderna Repeat COVID-19 Success In Influenza Market?
The company could have a significant competitive position thanks to the ability to rapidly develop and combine vaccines using mRNA technology.
Finance Watch: AbCellera, 4DMT, Nanobiotix IPOs Bring In $775m Combined
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals
Company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.